Table 1 ICU admission main characteristics, supportive therapies, outcome for all patients and ICU survivors or dead
From: Outcome of a cohort of severe cerebral venous thrombosis in intensive care
Total CVT n = 41 | ICU deaths n = 10 | ICU survivors n = 31 | p value | |
|---|---|---|---|---|
Age (years) | 47 (26–53) | 44.5 (30.8–52) | 47 (24–51.5) | 0.82 |
Sex female (%) | 30 (73.2) | 10 (100) | 20 (75.6) | 0.039 |
SAPS II | 41 (32–45) | 42.5 (41–52.5) | 35 (31.5–44.5) | 0.072 |
Delay for diagnosis (days) | 3 (1–7) | 3 (1–5.5) | 3 (1–7) | 0.73 |
Delay diagnosis–ICU admission (days) | 1 (0–3) | 0 (0–1) | 1 (1–4.5) | 0.029 |
GCS (lowest) | 7 (5–8) | 4 (3–6) | 8 (6–9) | 0.0004 |
Seizure in ICU [n (%)] | 18 (43.9) | 4 (40) | 14 (45.2) | 1.00 |
Mydriasis [n (%)] | 20 (48.8) | 10 (100) | 10 (32.3) | 0.0001 |
Hematoma [n (%)] | 32 (78.0) | 10 (100) | 22 (70.9) | 0.083 |
Heparin before admission [n (%)] | 25 (60.9) | 5 (50) | 20 (75.6) | 0.47 |
aPTT ratio > 2 within 48 h [n (%)] | 30 (80.5) | 5 (50) | 25 (80.6) | 0.098 |
Craniectomy (n (%)) | 16 (39.0) | 5 (50) | 11 (35.5) | 0.47 |
Endovascular treatment [n (%)] | 9 (21.9) | 3 (30) | 6 (19.4) | 0.66 |
CSF shunt [n (%)] | 7 (17.7) | 2 (20) | 5 (16.1) | 1.00 |
IV norepinephrine [n (%)] | 26 (63.4) | 9 (90) | 17 (54.8) | 0.063 |
MAP min day 1 (mmHg) | 76 (66–86) | 83 (70–98) | 76 (65–83) | 0.23 |
MAP min day 2 (mmHg) | 75 (71–84) | 73 (59–91) | 76 (72–83) | 0.56 |
Mechanical ventilation [n (%)] | 37 (90.2) | 10 (100) | 27 (87.1) | 0.55 |
Fluid balance day 1 (mL) | −188 (−482 to +393) | −350 (−1224 to −145) | −188 (−440 to +429) | 0.45 |
Fluid balance day 2 (mL) | 247 (−756 to +809) | −50 (−679 to +878) | 344 (−782 to +797) | 0.59 |
Natremia day 1 (mM) | 138 (135–142) | 139 (137–141) | 137 (135–142) | 0.64 |
Platelet count day 1 (109/L) | 231 (181–305) | 210 (162–239) | 240 (205–309) | 0.23 |
Glycemia day 1 (mM) | 7.1 (6.1–8.3) | 7.5 (6.2–10.8) | 7.1 (5.9–7.8) | 0.19 |
mRS at discharge | 4 (3–5) | 6 | 3 (2.5–4) | – |
mRS at 3 months (n = 23) | 3 (2–4) | – | 3 (2–4) | – |
mRS at 12 months (n = 18) | 2 (1–3) | – | 2 (1–3) | – |
mRS at last follow-up | 2 (1–6) | 6 | 2 (0.5–3) | – |